These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22847526)

  • 1. Platelet count or bleeding as the outcome in ITP trials?
    Arnold DM
    Am J Hematol; 2012 Oct; 87(10):945-6. PubMed ID: 22847526
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
    Pignatti F; Flores B; Jonsson B
    Am J Hematol; 2012 Oct; 87(10):943-4. PubMed ID: 22987253
    [No Abstract]   [Full Text] [Related]  

  • 3. TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
    Rodeghiero F
    Am J Hematol; 2012 Oct; 87(10):943. PubMed ID: 22847599
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M
    Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
    [No Abstract]   [Full Text] [Related]  

  • 5. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
    Altomare I; Wasser J; Pullarkat V
    Am J Hematol; 2012 Oct; 87(10):984-7. PubMed ID: 22729832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 7. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on romiplostim and eltrombopag indirect comparison.
    Cooper K; Matcham J; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2014 Jan; 30(1):129-130. PubMed ID: 24485057
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune thrombocytopenia during childhood: new approaches to classification and management.
    Buchanan GR
    J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
    [No Abstract]   [Full Text] [Related]  

  • 10. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
    Sartori R; Candiotto L; Ruggeri M; Tagariello G
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607
    [No Abstract]   [Full Text] [Related]  

  • 16. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 17. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
    Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
    Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.